185 related articles for article (PubMed ID: 18538869)
1. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
[TBL] [Abstract][Full Text] [Related]
2. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
Fantini J; Hammache D; Delézay O; Yahi N; André-Barrès C; Rico-Lattes I; Lattes A
J Biol Chem; 1997 Mar; 272(11):7245-52. PubMed ID: 9054420
[TBL] [Abstract][Full Text] [Related]
3. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
4. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
6. C-Glycoside analogues of beta-galactosylceramide with a simple ceramide substitute: synthesis and binding to HIV-1 gp120.
Augustin LA; Fantini J; Mootoo DR
Bioorg Med Chem; 2006 Feb; 14(4):1182-8. PubMed ID: 16216516
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity.
Faroux-Corlay B; Clary L; Gadras C; Hammache D; Greiner J; Santaella C; Aubertin AM; Vierling P; Fantini J
Carbohydr Res; 2000 Jul; 327(3):223-60. PubMed ID: 10945673
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
9. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
11. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
[TBL] [Abstract][Full Text] [Related]
12. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
13. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
14. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
Lai W; Huang L; Ho P; Li Z; Montefiori D; Chen CH
Antimicrob Agents Chemother; 2008 Jan; 52(1):128-36. PubMed ID: 17954689
[TBL] [Abstract][Full Text] [Related]
15. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.
Bobyk KD; Mandadapu SR; Lohith K; Guzzo C; Bhargava A; Lusso P; Bewley CA
Mol Pharm; 2017 Aug; 14(8):2681-2689. PubMed ID: 28494151
[TBL] [Abstract][Full Text] [Related]
16. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
17. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3.
Hammache D; Piéroni G; Yahi N; Delézay O; Koch N; Lafont H; Tamalet C; Fantini J
J Biol Chem; 1998 Apr; 273(14):7967-71. PubMed ID: 9525894
[TBL] [Abstract][Full Text] [Related]
18. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
19. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
[TBL] [Abstract][Full Text] [Related]
20. A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry.
Baleux F; Loureiro-Morais L; Hersant Y; Clayette P; Arenzana-Seisdedos F; Bonnaffé D; Lortat-Jacob H
Nat Chem Biol; 2009 Oct; 5(10):743-8. PubMed ID: 19734912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
